Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
105 | 141 | 28 | 8 | 28 |
Year wise citations received |
543 | 553 | 590 | 563 | 587 |
| Journal total citations count | 6601 |
| Journal Impact Factor | 6.49 |
| Journal 5 years Impact Factor | 12.17 |
| Journal CiteScore | 11.19 |
| Journal h-index | 41 |
| Journal h-index since 2016 | 26 |
Eissa, Nermin, Mohammed Al-Houqani, Adel Sadeq, Shreesh K. Ojha, Astrid Sasse, and Bassem Sadek. "Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder." Frontiers in neuroscience 12 (2018): 304. |
|
Chang, Chun-Hung, Hsien-Yuan Lane, Ping-Tao Tseng, Shaw-Ji Chen, Chieh-Yu Liu, and Chieh-Hsin Lin. "Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials." Journal of Psychopharmacology 33, no. 4 (2019): 436-448. |
|
Hsu, Mei-Chi, and Wen-Chen Ouyang. "Effects of integrated violence intervention on alexithymia, cognitive, and neurocognitive features of violence in schizophrenia: a randomized controlled trial." Brain sciences 11, no. 7 (2021): 837. |
|
Miller, Brian J., and David R. Goldsmith. "Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions." Neuropsychopharmacology 42, no. 1 (2017): 299-317. |
|
Smith, Conor C., Stella C. Martin, Kavitha Sugunan, Shelley J. Russek, Terrell T. Gibbs, and David H. Farb. "A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation." Molecular pharmacology 86, no. 4 (2014): 390-398. |
|
Eckfeld, Ariel Jenys. Neurocognitive and Social Cognitive Impairments in Early-Onset Psychosis and At-Risk Youth: Implications for Intervention Strategies. University of California, Los Angeles, 2017. |
|
Sommer, Iris E., Carrie E. Bearden, Edwin Van Dellen, Elemi J. Breetvelt, Sasja N. Duijff, Kim Maijer, Therese Van Amelsvoort et al. "Early interventions in risk groups for schizophrenia: what are we waiting for?." npj Schizophrenia 2, no. 1 (2016): 1-9. |
|
Leweke, F. Markus, Juliane K. Mueller, Bettina Lange, Stefan Fritze, Cristina E. Topor, Dagmar Koethe, and Cathrin Rohleder. "Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention." CNS drugs 32, no. 7 (2018): 605-619. |
|
de Bartolomeis, Andrea, Gianmarco Latte, Carmine Tomasetti, and Felice Iasevoli. "Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches." Molecular neurobiology 49, no. 1 (2014): 484-511. |
|
Schverer, Marina, Laurence Lanfumey, Etienne-Emile Baulieu, Nicolas Froger, and Isabelle Villey. "Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases." Pharmacology & therapeutics 191 (2018): 190-206. |
|
Sadek, Bassem, Ali Saad, Adel Sadeq, Fakhreya Jalal, and Holger Stark. "Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases." Behavioural brain research 312 (2016): 415-430. |
|
Avramopoulos, Dimitrios, Brad D. Pearce, John McGrath, Paula Wolyniec, Ruihua Wang, Nicole Eckart, Alexandros Hatzimanolis et al. "Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation." PloS one 10, no. 3 (2015): e0116696. |
|
Campellone, Timothy Ryan. Using outcomes to inform social decision-making in schizophrenia: Implications for motivation and functioning. University of California, Berkeley, 2016. |
|
Frydecka, Dorota, B?a?ej Misiak, Edyta Pawlak-Adamska, Lidia Karabon, Anna Tomkiewicz, Pawe? Sedlaczek, Andrzej Kiejna, and Jan Aleksander Besz?ej. "Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation." European archives of psychiatry and clinical neuroscience 265, no. 6 (2015): 449-459. |
|
Bartzokis, George, Po H. Lu, Chetan P. Amar, Erika P. Raven, Nicole R. Detore, Lori L. Altshuler, Jim Mintz et al. "Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory." Schizophrenia research 132, no. 1 (2011): 35-41. |
|
Ezeoke, Amaka, Andrew Mellor, Peter Buckley, and Brian Miller. "A systematic, quantitative review of blood autoantibodies in schizophrenia." Schizophrenia research 150, no. 1 (2013): 245-251. |
|
Chouinard, Guy, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, and Masaomi Iyo. "Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy." Psychotherapy and Psychosomatics 86, no. 4 (2017): 189-219. |
|
Hartwig, Fernando Pires, Maria Carolina Borges, Bernardo Lessa Horta, Jack Bowden, and George Davey Smith. "Inflammatory biomarkers and risk of schizophrenia: a 2-sample mendelian randomization study." JAMA psychiatry 74, no. 12 (2017): 1226-1233. |
|
Cai, HuaLin, Ting Cao, Xiang Zhou, and Jeffrey K. Yao. "Neurosteroids in schizophrenia: pathogenic and therapeutic implications." Frontiers in psychiatry 9 (2018): 73. |
|
Bartzokis, George. "Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments." Neuropharmacology 62, no. 7 (2012): 2137-2153. |
|